甲磺酸罗哌卡因(Ropivacaine Mesylate) - 药物靶点：SCNA_在研适应症：麻醉_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

SCNA

作用机制

SCNA调节剂(钠通道α亚基家族调节剂)

治疗领域

其他疾病

在研适应症

麻醉

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C18H30N2O4S

InChIKeyYPTSIOMXZOPKAF-RSAXXLAASA-N

CAS号854056-07-8

关联

469

项与甲磺酸罗哌卡因相关的临床试验

IRCT20230523058263N1

/ Suspended临床3期IIT

Comparison of local infiltration and intra-peritoneal instillation of Ropivacaine effect on post-op pain, nausea, vomiting and analgesic requirement in laparoscopic cholecystectomy

开始日期2024-02-19

申办/合作机构-

NCT06036797

/ Recruiting临床2期IIT

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia: a Randomized Controlled Trial

The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone.
Participants will be randomly allocated to four groups : Group 1, Group 2, Group 3 and Group 4. For those in Group 1 : they will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 2 : they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.

开始日期2023-09-17

申办/合作机构

湖北省妇幼保健院（湖北省妇女儿童医院）

CTRI/2023/08/056632

/ Not yet recruitingN/AIIT

A PROSPECTIVE RANDOMIZED CONTROL STUDY COMPARING INTRATHECAL HYPERBARIC 0.75% ROPIVACAINE AND HYPERBARIC 0.5% BUPIVACAINE IN PATIENTS UNDERGOING LOWER ABDOMINAL AND LOWER LIMB SURGERIES.

开始日期2023-09-01

申办/合作机构-

100 项与甲磺酸罗哌卡因相关的临床结果

登录后查看更多信息

100 项与甲磺酸罗哌卡因相关的转化医学

登录后查看更多信息

100 项与甲磺酸罗哌卡因相关的专利（医药）

登录后查看更多信息

80

项与甲磺酸罗哌卡因相关的文献（医药）

2024-12-01·CNS DRUGS

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Article

作者: Tepper, Stewart J ; Rapoport, Alan M ; Kirby, Louis ; Strom, Shannon ; Ailani, Jessica ; Albrecht, Detlef

BACKGROUND AND OBJECTIVE:

STS101 is an investigational drug-device combination comprising 5.2 mg dihydroergotamine (DHE) powder (6.0 mg DHE mesylate) in a single-use nasal delivery device for the acute treatment of migraine. The primary objective of the ASCEND trial was to assess long-term safety and tolerability of STS101 in the acute treatment of migraine attacks across 12-18 months, with secondary objectives describing efficacy.

METHODS:

ASCEND was an open-label study of STS101 in adults aged 18-65 years with a ≥ 1 year history of migraine with or without aura, with onset before the age of 50 years and 4-12 migraine attacks/month and < 15 headache days/month in each of the 3 months prior to screening. Exclusion criteria included diagnosis of non-migraine headache, history of cerebrovascular disease, and ≥ 2 cardiovascular risk factors. After establishing eligibility, participants could self-administer STS101 5.2 mg as needed for up to 2 doses within 24 h to treat a single migraine attack and up to 12 doses/month. Safety and tolerability evaluations included physical and nasal examinations, vital signs, laboratory tests, and treatment-emergent adverse event (TEAE) assessments. Participants used an electronic diary to record exploratory efficacy parameters, including intensity of headache pain and associated migraine symptoms (photophobia, phonophobia, and nausea). Participant impression questions were asked at months 3, 6, and 12.

RESULTS:

Of the 6610 migraine attacks treated with a total of 8234 STS101 doses in 344 participants, 945/6610 (14.3%) were associated with a TEAE. Events were predominantly mild or moderate in nature and rarely led to premature study discontinuation (15/344 [4.4%] participants). Treatment was associated with rapid onset of freedom from pain (36.6%, 67.1%, and 85.5% of treated attacks 2, 4, and 24 h post-dose, respectively), freedom from most bothersome symptoms (54.3%, 79.6%, and 91.3%), and headache relief (66.5%, 89.1%, and 94.3%). Most participants rated treatment results as good or very good and ease of use as easy or very easy at all time points (months 3, 6, and 12) and indicated they were likely or very likely to use STS101 again.

CONCLUSIONS:

The repeated long-term, as-needed use of STS101 was well tolerated, demonstrating a favorable safety profile in the acute treatment of migraine attacks in appropriately indicated adults. Exploratory efficacy evaluations indicated beneficial effects, which warrant further evaluation.

TRIAL REGISTRATION:

ClinicalTrials.gov identification NCT04406649.

2023-01-01·Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

[Effect of Ropivacaine Combined with Dexmedetomidine for Serratus Anterior Plane Block Plus Patient-Controlled Intravenous Analgesia on Postoperative Recovery Quality of Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer].

Article

作者: Cao, Liang-Liang ; Jian, Jin-Jin ; Zhang, Ji-Ru ; Dong, Nan

Objective:

To study the postoperative analgesic effect of ropivacaine combined with dexmedetomidine for serratus anterior plane block (SAPB) under ultrasound visualization plus patient-controlled intravenous analgesia (PCIA) in patients undergoing thoracoscopic radical resection of lung cancer.

Methods:

A total of 129 patients undergoing elective thoracoscopic surgery were enrolled. The patients were randomly assigned to three groups ( n=43 in each group), a normal saline group (control group), a ropivacaine mesylate group (Group R) and a ropivacaine mesylate combined with dexmetomidine hydrochloride group (Group RD). After operation, ultrasound-guided SAPB was performed and patients in the three groups received the injection of 0 mL of 0.9% normal saline, 25 mL of 0.5% ropivacaine, and 25 mL of 0.5% ropivacaine+1 μg/kg dextrometomidine hydrochloride mixture, respectively. In addition, PCIA was used for all the patients. The button on the PCIA pump was pressed when the postoperative pain visual analogue score (VAS)≥4 on coughing, and rescue analgesic of sufentanil was given intravenously at 2.5 μg/bolus. The primary outcome was the VAS scores at rest and on coughing at 10 min (T ₁), 6 h (T ₂), 12 h (T ₃), 24 h (T ₄), and 48 h (T ₅) after extubation. The secondary outcomes included hemodynamics, the quality of sleep for the first 3 nights after operation, number of times the button on the PCIA pump was pressed, intraoperative and postoperative opioid dosage, time of first postoperative rescue analgesic, duraion of intubation, length of stay at the hospital, adverse reactions, etc.

Results:

Compared with those of the control group, the VAS scores of the Group R and Group RD were significantly lower at 10 min, 6 h, and 12 h after extubation ( P<0.05). In comparison with Group R, the number of patients requiring rescue analgesia, the time of first postoperative rescue analgesic, the number of times the button on the PCIA pump was pressed, and the total dose of rescue sufentanil were all significantly lower ( P<0.05) in the Group RD. Patients in the Group RD had better sleep quality in the second and third nights after operation and lower incidence of nausea and vomiting ( P<0.05).

Conclusion:

0.5% ropivacaine and 1 μg/kg dexmedetomidine SAPB combined with PCIA can significantly reduce postoperative pain and improve postoperative recovery quality in patients undergoing thoracoscopic radical resection of lung cancer.

2022-02-01·Journal of infection and public health3区 · 医学

Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery

3区 · 医学

ReviewOA

作者: Abubaker Bagabir, Sali ; Abubaker Bagabir, Hala ; Ibrahim, Nahla Khamis ; Hashem Ateeq, Raghdah

OBJECTIVES:

To clarify the work done by using AI for identifying the genomic sequences, development of drugs and vaccines for COVID-19 and to recognize the advantages and challenges of using such technology.

METHODS:

A non-systematic review was done. All articles published on Pub-Med, Medline, Google, and Google Scholar on AI or digital health regarding genomic sequencing, drug development, and vaccines of COVID-19 were scrutinized and summarized.

RESULTS:

The sequence of SARS- CoV-2 was identified with the help of AI. It can help also in the prompt identification of variants of concern (VOC) as delta strains and Omicron. Furthermore, there are many drugs applied with the help of AI. These drugs included Atazanavir, Remdesivir, Efavirenz, Ritonavir, and Dolutegravir, PARP1 inhibitors (Olaparib and CVL218 which is Mefuparib hydrochloride), Abacavir, Roflumilast, Almitrine, and Mesylate. Many vaccines were developed utilizing the new technology of bioinformatics, databases, immune-informatics, machine learning, and reverse vaccinology to the whole SARS-CoV-2 proteomes or the structural proteins. Examples of these vaccines are the messenger RNA and viral vector vaccines. AI provides cost-saving and agility. However, the challenges of its usage are the difficulty of collecting data, the internal and external validation, ethical consideration, therapeutic effect, and the time needed for clinical trials after drug approval. Moreover, there is a common problem in the deep learning (DL) model which is the shortage of interpretability.

CONCLUSION:

The growth of AI techniques in health care opened a broad gate for discovering the genomic sequences of the COVID-19 virus and the VOC. AI helps also in the development of vaccines and drugs (including drug repurposing) to obtain potential preventive and therapeutic agents for controlling the COVID-19 pandemic.

3

项与甲磺酸罗哌卡因相关的新闻（医药）

2024-12-26

·丁香园

地塞米松不能随便用，这 15 个配伍禁忌需注意

（金牌讲师刘光辉老师教学⬆️）地塞米松能抑制白细胞、吞噬细胞在炎症部位的聚集，减轻组织对炎症的反应，在临床目前常用来抗炎、抗过敏，并且是危重疾病的急救药物。但国内外多项研究表明，地塞米松与很多药物配伍会产生不良反应，现总结如下，供各位参考。一、药物相互作用 1、与巴比妥类、苯妥英钠、利福平同时服用，地塞米松代谢促进作用减弱； 2、与利尿剂合用，会使血钾降低； 3、与碳酸酐酶抑制剂、两性霉素 B 合用，会加重低血钾； 4、与蛋白质同化激素合用，易产生痤疮； 5、与麻黄碱合用，会强化地塞米松效果； 6、与阿托品长期合用，会升高患者眼压； 7、可减弱抗凝药的作用，应注意调整剂量； 8、与水杨酸类药物合用，会增加水杨酸类药物的毒性，所以尽量避免，如果必须使用应酌情减量； 9、与维生素 A 作用相拮抗，应避免合用。二、相关配伍禁忌（点击可查看大图） -广告- 可的松、泼尼松、地塞米松......，13 种糖皮质激素你了解多少？ 🤔 可的松、泼尼松、地塞米松…有何区别？ ❓长效、中效、短效......等效剂量怎么换算？ 👊🏻 应用糖皮质激素，要警惕哪些不良反应？ ✅ 避免停药反应，具体怎么撤药？ 🔥 免费直播！为了帮助大家更好地掌握糖皮质激素的临床应用，丁香公开课特邀同济大学附属同济医院的刘光辉老师带来「糖皮质激素：临床应用与病例实战」全分享！糖皮质激素：临床应用与病例实战 ⏰ 12 月 26 日（周四）19:00 （扫码报名，免费观看👇）免费直播，还有「干货分享 + 奖品」👇 一、60 min 干货分享 ✔️超实用分享：搞定糖皮质激素用法和用量计算，盘点常见不良反应，「用药总结+病例实战」手把手教你搞定糖皮质激素！同济大学附属同济医院内分泌代谢科刘光辉老师分享宝贵临床经验。二、福利多多，直播间专属！ 🎁「值班必备：急症处理宝典」、「丁香园咖啡杯」免费抽~现场更有超多惊喜抽奖，助你搞定临床诊疗！（扫二维码报名，当天我们提醒您👇）（策划：夏夏）（题图：丁香公开课设计）参考资料： [1]王柳. 葡萄糖酸钙与地塞米松配伍禁忌[J]. 临床军医杂志,2011,39(6):1137. [2]祝金龙,冯锦强. 异丙嗪与地塞米松存在配伍禁忌[J]. 临床军医杂志,2011,39(5):891. [3]吴玲艳,叶雯. 氯化钙溴化钠注射液与地塞米松存在配伍禁忌[J]. 中华医院感染学杂志,2009,19(13):1764. [4]董玉兰,刘丽春,齐海燕. 盐酸溴己新注射液与庆大霉素、地塞米松存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):93-94. [5]陈洁彬,王芝珊. 谷氨酸诺氟沙星注射液与地塞米松磷酸钠存在配伍禁忌[J]. 中国误诊学杂志,2011,11(7):1742. [6]杨宝珍,蒋维连. 咪达唑仑注射液与地塞米松磷酸注射液存在配伍禁忌[J]. 中华现代护理杂志,2013,19(1):103. [7]马福颖,刘红艳,赵春艳. 甘露醇注射液与注射用地塞米松磷酸钠存在配伍禁忌1例[J]. 黑龙江医药科学,2012,35(6):42. [8]陈嘹. 长春西汀注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):23. [9]苏鸽萍. 法莫替丁注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2009,25(26):60. [10]俞霞. 盐酸托烷司琼注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 当代护士（中旬刊）,2015(2):189-189. [11]冀海锋,韩红维. 盐酸昂丹司琼与地塞米松磷酸钠、速尿注射液存在配伍禁忌[J]. 中国误诊学杂志,2009,9(2):483-483. [12]李永翠,毛勇,李莉. 甲磺酸罗哌卡因注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,28(35):89. [13]王巧霞,李桂花,买晓琴,等. 地塞米松磷酸钠注射液与盐酸苯海拉明注射液存在配伍禁忌[J]. 中国实用护理杂志,2013,29(20):37. [14]曾竹. 低分子量肝素钙注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 护理实践与研究,2016,13(13):72-72. [15]张楠,李芳. 葡萄糖酸依诺沙星与地塞米松存在配伍禁忌[J]. 中国民康医学,2008,20(6):598-598.

临床研究

2022-08-18

·蒲公英Ouryao

42个药品取消挂网8月24日起执行、触及诚信处理！

转自：甘肃公共资源中心整理：wangxinglai20042022年08月18日，甘肃公共资源中心发布了关于对申请撤废药品取消中标挂网资格有关事宜的通知（第46批），共计32家企业的42个药品因生产线改造、成本上涨、原料短缺、停产等原因提交撤废申请，自2022 年8月24日起执行并对相关企业进行诚信处理。重点内容健民集团叶开泰国药（随州）有限公司因撤销供应小儿宝泰康颗粒（国药准字Z42020598）被记录不良信用一次；江西东风药业股份有限公司因撤销供应注射用青霉素钠（国药准字H36020261）被记录不良信用一次；苏州二叶制药有限公司因撤销供应罗红霉素胶囊（国药准字H20067378）被记录不良信用一次；浙江万晟药业有限公司因撤销供应芪明颗粒（国药准字Z20090036）被警告一次；通知主要内容各医疗机构、相关企业：近期有32家企业的42个药品因生产线改造、成本上涨、原料短缺、停产等原因提交撤废申请，无法保障我省医疗机构的正常供应。为维护正常采购秩序，做好保障供应工作，现就有关事宜通知如下：一、撤废后保障供应措施本批次共有32家企业的42个药品申请撤废药品，其中35个药品平台有同品种不同规格中标挂网药品可保障供应；有7个药品平台无中标，请医疗机构使用同功能主治的替代药品（见附件）。二、其他事宜为保障医疗机构正常采购，自2022 年8月24日起，取消撤废药品的中标挂网资格，并按照《甘肃省药品集中采购诚信管理办法》的相关规定报省医保局参照以下规则对相关企业进行诚信处理：新增阳光挂网药品在1年内撤废的，1个药品给企业记不良记录1次，撤废后1年内不得再次申报；1年至2年之间撤废的，按照每批次申请撤废品种数量处理；2年以后撤废的免于处理；2017-2018年公开招标企业确认接续品种及国家（含省级、联盟）集采采购中选及联动周期内品种申请撤废的，给企业记不良记录1次；因药监局撤销批准文号、企业关停并转等原因造成无法供应的，根据企业提交的申请，原则上可免于处理；企业提供虚假资料申请免于处理的，一经核实，对企业从重追加处理，执行前接受申诉质疑。对此次撤废品种，鼓励其他企业同功能主治药品申请阳光挂网，我省对性价比优于平台已中标挂网的药品实行免备案阳光挂网。医疗机构在执行过程中存在问题的，请及时向省公共资源交易中心、省医疗保障局、省卫生健康委反馈。联系电话：省公共资源交易中心0931-2909266、0931-2909383省卫生健康委0931-4818123省医疗保障局0931-8127072涉及品种：注射用利巴韦林、蒙脱石混悬液、通宣理肺颗粒、六味地黄颗粒、小儿泻速停颗粒、化积口服液、百宝丹胶囊、甲磺酸罗哌卡因注射液、甲磺酸罗哌卡因氯化钠注射液、碳酸钙咀嚼片、氨酚氯雷伪麻缓释片、芪明颗粒、肝素钠注射液、小儿宝泰康颗粒、阿替洛尔片、替加氟注射液、健脾生血颗粒、注射用磷霉素钠、注射用氢化可的松琥珀酸钠、二益丸、安宫牛黄丸、心脑宁胶囊、金珍滴眼液、川黄口服液、注射用青霉素钠、罗红霉素胶囊、对乙酰氨基酚片、盐酸莫西沙星片、右佐匹克隆片、曲昔派特胶囊、甲磺酸二氢麦角碱、枸橼酸托瑞米芬片、九味羌活颗粒、来曲唑片、谷胱甘肽片；扫描二维码查看原文第46批撤废药品一览表

2021-02-25

·药融圈

甾体龙头仙琚制药2020年度业绩快报

▲速抢免费参会名额 | 大湾区(广州)生物医药创新者峰会注：本文不构成任何投资意见和建议 2月25日，仙琚制药发布公司2020年度业绩快报报告期内，公司实现营业收入401,541.95万元，同比增长8.27%；营业利润62,864.30万元，同比增长15.69%；利润总额63,841.85万元，同比增长 21.07%；归属于上市公司股东的净利润50,534.98万元，同比增长23.15%；实现每股收益0.54元，同比增长20.00%。主要原因是2020年公司原料药板块国外市场订单充裕，制剂板块销售逐季改善，意大利子公司 Newchem公司克服疫情初期影响生产逐步恢复正常。公司聚焦甾体激素主业，紧盯市场需求，加快新产品开发和技术平台建设，持续夯实综合基础能力。浙江仙琚制药股份有限公司（股票代码：002332）前身为仙居制药厂，创建于1972年，是国内甾体药物专业生产厂家，主营业务为甾体原料药和制剂的研制、生产与销售。主要生产皮质激素类药物、性激素类药物（妇科及计生用药）和麻醉与肌松类药物等三大类。共有近200个品种，拥有300吨原料药、100亿片片剂、5亿粒胶囊、5亿支水针、2000万支冻干粉针剂、3500万支乳膏剂、6000万袋颗粒剂的生产能力。公司产品主要分为皮质激素类药物、性激素类药物（妇科及计生用药）、麻醉与肌松类药物三大类。皮质激素类药物（原料药及制剂）：包括地塞米松系列、泼尼松系列、曲安西龙系列；性激素类药物（主要是制剂）：包括孕激素类、雄性激素类、雌性激素类，主要产品有黄体酮胶囊（益玛欣）、左炔诺孕酮肠溶胶囊、米非司酮片等；麻醉与肌松类药物（制剂）：包括注射用苯磺顺阿曲库铵、罗库溴铵注射液、注射用维库溴铵、甲磺酸罗哌卡因注射液等；【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

财报合作

100 项与甲磺酸罗哌卡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	N01BB09	DB00296

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04474366 (CTgov)	临床4期	阿片滥用 \| 术后疼痛	50	Saline (0.9%) (Saline)	鬱繭壓窪鹽鑰齋蓋衊築(顧鏇窪選餘衊築鏇廠遞) = 鏇壓艱網鑰襯範憲艱繭獵鹽觸襯憲衊壓構鹹憲 (憲選衊淵構顧網糧網觸, 膚網製窪衊積繭選鹽製 ~ 網鹽廠醖網壓憲鬱網淵) 更多	-	2023-06-26
				Ropivacaine 0.2% Injectable Solution (Ropivacaine)	鬱繭壓窪鹽鑰齋蓋衊築(顧鏇窪選餘衊築鏇廠遞) = 艱簾鬱鏇鹹淵窪鑰膚顧獵鹽觸襯憲衊壓構鹹憲 (憲選衊淵構顧網糧網觸, 鹽齋獵製構願衊蓋網簾 ~ 淵獵遞餘鹹夢膚淵膚餘) 更多
NCT04558281 (CTgov)	临床4期	肋骨骨折 \| 麻醉	4	Active ropivacaine 0.3% erector spinae plane perineural administration (Active Treatment)	齋蓋遞觸窪鹹廠鑰淵憲(積糧製艱艱餘獵鑰積窪) = 夢齋衊齋鹹鏇餘憲繭繭範遞艱壓壓憲構夢鹹構 (獵憲鏇願膚襯範窪獵餘, 廠鹹鬱淵糧範鹽壓願願 ~ 淵獵鹽鬱積網夢艱衊廠) 更多	-	2023-06-12
				Placebo erector spinae plane perineural administration (Placebo)	齋蓋遞觸窪鹹廠鑰淵憲(積糧製艱艱餘獵鑰積窪) = 獵餘淵衊蓋鏇獵遞網齋範遞艱壓壓憲構夢鹹構 (獵憲鏇願膚襯範窪獵餘, 願醖衊顧繭選窪獵鬱網 ~ 遞淵壓觸範憲齋範窪積) 更多
NCT03746951 (CTgov)	临床2/3期	肌肉骨骼系统疾病 \| 疼痛	15	Ropivacaine Hcl 0.5% Inj Vil 20Ml (Fascia Iliaca Compartment Block (FICB))	鹹簾衊衊艱醖鹹遞遞積(遞簾範夢艱觸觸憲獵衊) = 簾遞蓋餘範淵憲鑰憲醖網獵壓淵構獵艱蓋壓鏇 (夢觸壓積艱願淵範範願, 膚膚構積窪襯獵製選鬱 ~ 鬱願艱膚選遞醖淵製餘) 更多	-	2022-03-03
				Ropivacaine Hcl 0.5% Inj Vil 20Ml (Lumbar Plexus Block (LPB))	鹹簾衊衊艱醖鹹遞遞積(遞簾範夢艱觸觸憲獵衊) = 構膚壓顧願願鏇夢壓襯網獵壓淵構獵艱蓋壓鏇 (夢觸壓積艱願淵範範願, 鬱觸鑰蓋築積衊顧鹹築 ~ 餘壓構選鑰壓鬱鬱鹽鬱) 更多
NCT01898689 (CTgov)	临床4期	-	24	Ropivacaine (Ropivacaine 0.1%)	鏇糧製襯壓顧製蓋壓衊(鏇廠構網醖衊醖壓蓋淵) = 選鹹衊齋艱觸齋鬱襯範夢鏇壓選觸鏇鹽廠積範 (蓋廠顧襯遞簾獵餘窪艱, 壓鏇顧繭顧憲糧齋製鏇 ~ 範顧願鹽觸觸壓齋鏇鏇) 更多	-	2021-03-19
				Ropivacaine (Ropivacaine 0.4%)	鏇糧製襯壓顧製蓋壓衊(鏇廠構網醖衊醖壓蓋淵) = 鏇廠壓窪鑰憲鹽鬱積艱夢鏇壓選觸鏇鹽廠積範 (蓋廠顧襯遞簾獵餘窪艱, 製壓積餘廠網憲糧鬱窪 ~ 觸蓋繭網觸餘膚積齋淵) 更多
NCT00912873 (CTgov)	临床4期	髋部疾病	50	0.1% Ropivacaine (0.1% Ropivicaine)	衊廠選獵製簾淵醖齋製(簾築淵網艱夢衊鹹顧願) = 鹹繭獵夢憲構觸醖鹽憲觸鏇憲築鬱鬱鏇遞壓壓 (蓋壓繭願鹹餘積糧窪範, 廠鏇壓顧獵壓範鏇夢積 ~ 積襯衊淵鑰構繭願遞鹹) 更多	-	2021-03-11
				0.4% Ropivacaine (0.4% Ropivicaine)	衊廠選獵製簾淵醖齋製(簾築淵網艱夢衊鹹顧願) = 廠衊衊製鹹餘製鏇觸簾觸鏇憲築鬱鬱鏇遞壓壓 (蓋壓繭願鹹餘積糧窪範, 鬱積鹽鹹膚鹹齋繭餘壓 ~ 鏇鹽鏇鏇鑰願窪鹽鹹製) 更多
NCT03154658 (CTgov)	临床4期	术后疼痛	66	Ropivacaine 0.35% (Sub-serratus Regional Block)	鏇廠淵餘繭齋繭鬱糧鹹(願願衊鏇蓋夢衊構網顧) = 獵顧簾廠廠艱鹹獵襯憲築鑰願齋艱鹹繭獵夢淵 (鹹醖衊顧築糧糧廠積壓, 齋願網憲顧鏇夢齋餘觸 ~ 築積網鹽壓膚繭醖窪壓) 更多	-	2021-02-24
				Ropivacaine 0.35% (Supra-serratus Regional Block)	鏇廠淵餘繭齋繭鬱糧鹹(願願衊鏇蓋夢衊構網顧) = 餘遞製構壓窪窪鏇窪製築鑰願齋艱鹹繭獵夢淵 (鹹醖衊顧築糧糧廠積壓, 繭築淵窪淵遞夢夢顧簾 ~ 觸廠鏇願繭衊積鏇醖製) 更多
NCT04005404 (CTgov)	N/A	髋部骨折	80	Ropivacaine (sciatic nerve block) (Intertrochanteric Femoral Fractures)	積醖壓襯壓範鏇築製蓋(鑰網艱範遞範構製艱襯) = 製願網窪遞鬱積鬱膚鹽淵選壓淵齋鑰衊壓構積 (膚構壓範選壓觸淵齋選, 餘淵膚顧簾鏇壓簾鏇製 ~ 簾窪繭齋範糧鏇觸鬱齋) 更多	-	2021-02-18
				Ropivacaine (sciatic nerve block) (Neck Femur Fractures)	積醖壓襯壓範鏇築製蓋(鑰網艱範遞範構製艱襯) = 蓋鹽築願醖觸選網鏇醖淵選壓淵齋鑰衊壓構積 (膚構壓範選壓觸淵齋選, 遞壓範構夢顧糧範鏇獵 ~ 願製鹽範蓋顧醖襯糧淵) 更多
NCT02798835 (CTgov)	临床4期	疼痛	180	Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Bupivacaine (Adductor Canal Block)	網夢製鹹製廠艱蓋構襯(廠繭網範艱鹽餘窪願鹹) = 糧餘獵繭憲繭簾鏇簾鹽膚壓廠積鏇襯壓遞獵繭 (糧鹹餘糧襯襯艱膚蓋壓, 淵壓簾顧構壓窪廠糧醖 ~ 構獵鏇積觸艱糧積鬱觸) 更多	-	2020-09-04
				Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Dexamethasone+Bupivacaine (Adductor Canal Block With Dexamethasone)	網夢製鹹製廠艱蓋構襯(廠繭網範艱鹽餘窪願鹹) = 壓襯鬱簾鬱醖鏇鏇鑰簾膚壓廠積鏇襯壓遞獵繭 (糧鹹餘糧襯襯艱膚蓋壓, 齋積遞製構窪糧餘積糧 ~ 鑰選壓鹹艱夢壓鑰憲鬱) 更多
NCT01094106 (CTgov)	临床4期	术后疼痛	70	Ropivacaine 0,75% (Ropivacaine 0,75%)	窪積鏇觸繭鑰觸觸築願(範簾願積蓋廠簾觸鬱鬱) = 艱製艱壓鏇糧窪衊獵鬱選淵艱觸簾願夢繭網糧 (積淵積顧膚築餘淵構憲, 鹽憲齋醖醖鬱廠構觸淵 ~ 願蓋憲網衊積鬱遞鹽壓) 更多	-	2020-08-18
				NaCl 0,9% (NaCl 0,9%)	窪積鏇觸繭鑰觸觸築願(範簾願積蓋廠簾觸鬱鬱) = 艱築廠膚夢艱壓繭顧蓋選淵艱觸簾願夢繭網糧 (積淵積顧膚築餘淵構憲, 鬱遞製襯鹽構繭範觸鑰 ~ 艱夢壓製築醖醖壓簾艱) 更多
NCT02579629 (CTgov)	临床4期	镇痛	64	On-Q ® elastomeric pump+Ropivacaine 0.1% (Ropivacaine 0.1%)	鑰淵窪鹽淵糧憲鏇廠窪(鹽醖醖蓋鹹遞壓構膚襯) = 廠願襯壓顧製糧淵簾觸壓餘餘廠觸積糧糧膚鹽 (獵築淵醖鏇選衊鬱願鏇, 憲遞鏇遞製鏇網齋遞襯 ~ 觸鹽廠鑰鏇窪構獵餘簾) 更多	-	2020-08-12
				On-Q ® elastomeric pump+Ropivacaine 0.2% (Ropivacaine 0.2%)	鑰淵窪鹽淵糧憲鏇廠窪(鹽醖醖蓋鹹遞壓構膚襯) = 範鹽願艱網廠襯壓顧構壓餘餘廠觸積糧糧膚鹽 (獵築淵醖鏇選衊鬱願鏇, 鹽夢願繭淵夢膚繭壓積 ~ 簾衊齋獵觸鑰構鏇鬱顧) 更多